Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans.

Raffaella Melzi, Paola Maffi, Rita Nano, Valeria Sordi, Alessia Mercalli, Marina Scavini, Antonio Secchi, Ezio Bonifacio, Lorenzo Piemonti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In this study we examined the effect of rapamycin (RAPA), a key component of the immunosuppressive regimen in clinical islet transplantation, on islet engraftment and function in vivo. Diabetic C57BL/6 or BALB/C recipient mice were transplanted with 350 syngeneic islets through the portal vein (PV-Tx; C57BL/6 n = 60; BALB/C n = 22) and treated with once-daily oral RAPA (1 mg/kg) or vehicle. No differences in post-transplant blood glucose concentrations and glucose tolerance were observed between RAPA- and vehicle-treated mice. The impact of RAPA on human islet engraftment was assessed in 10 patients with type 1 diabetes treated with : 0.1 mg/kg/day rapamycin before islet transplantation. Compared to non pre-treated islet transplant recipients (n = 12), RAPA pre-treated patients had increased blood RAPA concentrations (p = 0.006) and fasting C-peptide concentrations (p = 0.005) in the two weeks post-transplant. RAPA pre-treatment was associated with a reduction in chemokines CCL2 and CCL3 concentrations pre-transplant (p <0.01), and a dampened chemokine response (p = 0.005) post-transplant. Concordantly, in vitro RAPA inhibited the secretion of CCL2 and CCL3 by monocytes. Rapamycin does not adversely affect intrahepatic islet engraftment in the mouse, and potentially improves islet engraftment in humans by an anti-inflammatory mechanism.

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalIslets
Volume1
Issue number1
Publication statusPublished - Jul 2009

Fingerprint

Sirolimus
Transplants
Islets of Langerhans Transplantation
Inbred BALB C Mouse
Chemokine CCL3
Chemokine CCL2
C-Peptide
Immunosuppressive Agents
Portal Vein
Type 1 Diabetes Mellitus
Chemokines
Blood Glucose
Monocytes
Fasting
Anti-Inflammatory Agents
Glucose

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans. / Melzi, Raffaella; Maffi, Paola; Nano, Rita; Sordi, Valeria; Mercalli, Alessia; Scavini, Marina; Secchi, Antonio; Bonifacio, Ezio; Piemonti, Lorenzo.

In: Islets, Vol. 1, No. 1, 07.2009, p. 42-49.

Research output: Contribution to journalArticle

@article{bc5d9f3c9ca04ceaa9c72be2ea4a9293,
title = "Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans.",
abstract = "In this study we examined the effect of rapamycin (RAPA), a key component of the immunosuppressive regimen in clinical islet transplantation, on islet engraftment and function in vivo. Diabetic C57BL/6 or BALB/C recipient mice were transplanted with 350 syngeneic islets through the portal vein (PV-Tx; C57BL/6 n = 60; BALB/C n = 22) and treated with once-daily oral RAPA (1 mg/kg) or vehicle. No differences in post-transplant blood glucose concentrations and glucose tolerance were observed between RAPA- and vehicle-treated mice. The impact of RAPA on human islet engraftment was assessed in 10 patients with type 1 diabetes treated with : 0.1 mg/kg/day rapamycin before islet transplantation. Compared to non pre-treated islet transplant recipients (n = 12), RAPA pre-treated patients had increased blood RAPA concentrations (p = 0.006) and fasting C-peptide concentrations (p = 0.005) in the two weeks post-transplant. RAPA pre-treatment was associated with a reduction in chemokines CCL2 and CCL3 concentrations pre-transplant (p <0.01), and a dampened chemokine response (p = 0.005) post-transplant. Concordantly, in vitro RAPA inhibited the secretion of CCL2 and CCL3 by monocytes. Rapamycin does not adversely affect intrahepatic islet engraftment in the mouse, and potentially improves islet engraftment in humans by an anti-inflammatory mechanism.",
author = "Raffaella Melzi and Paola Maffi and Rita Nano and Valeria Sordi and Alessia Mercalli and Marina Scavini and Antonio Secchi and Ezio Bonifacio and Lorenzo Piemonti",
year = "2009",
month = "7",
language = "English",
volume = "1",
pages = "42--49",
journal = "Islets",
issn = "1938-2014",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans.

AU - Melzi, Raffaella

AU - Maffi, Paola

AU - Nano, Rita

AU - Sordi, Valeria

AU - Mercalli, Alessia

AU - Scavini, Marina

AU - Secchi, Antonio

AU - Bonifacio, Ezio

AU - Piemonti, Lorenzo

PY - 2009/7

Y1 - 2009/7

N2 - In this study we examined the effect of rapamycin (RAPA), a key component of the immunosuppressive regimen in clinical islet transplantation, on islet engraftment and function in vivo. Diabetic C57BL/6 or BALB/C recipient mice were transplanted with 350 syngeneic islets through the portal vein (PV-Tx; C57BL/6 n = 60; BALB/C n = 22) and treated with once-daily oral RAPA (1 mg/kg) or vehicle. No differences in post-transplant blood glucose concentrations and glucose tolerance were observed between RAPA- and vehicle-treated mice. The impact of RAPA on human islet engraftment was assessed in 10 patients with type 1 diabetes treated with : 0.1 mg/kg/day rapamycin before islet transplantation. Compared to non pre-treated islet transplant recipients (n = 12), RAPA pre-treated patients had increased blood RAPA concentrations (p = 0.006) and fasting C-peptide concentrations (p = 0.005) in the two weeks post-transplant. RAPA pre-treatment was associated with a reduction in chemokines CCL2 and CCL3 concentrations pre-transplant (p <0.01), and a dampened chemokine response (p = 0.005) post-transplant. Concordantly, in vitro RAPA inhibited the secretion of CCL2 and CCL3 by monocytes. Rapamycin does not adversely affect intrahepatic islet engraftment in the mouse, and potentially improves islet engraftment in humans by an anti-inflammatory mechanism.

AB - In this study we examined the effect of rapamycin (RAPA), a key component of the immunosuppressive regimen in clinical islet transplantation, on islet engraftment and function in vivo. Diabetic C57BL/6 or BALB/C recipient mice were transplanted with 350 syngeneic islets through the portal vein (PV-Tx; C57BL/6 n = 60; BALB/C n = 22) and treated with once-daily oral RAPA (1 mg/kg) or vehicle. No differences in post-transplant blood glucose concentrations and glucose tolerance were observed between RAPA- and vehicle-treated mice. The impact of RAPA on human islet engraftment was assessed in 10 patients with type 1 diabetes treated with : 0.1 mg/kg/day rapamycin before islet transplantation. Compared to non pre-treated islet transplant recipients (n = 12), RAPA pre-treated patients had increased blood RAPA concentrations (p = 0.006) and fasting C-peptide concentrations (p = 0.005) in the two weeks post-transplant. RAPA pre-treatment was associated with a reduction in chemokines CCL2 and CCL3 concentrations pre-transplant (p <0.01), and a dampened chemokine response (p = 0.005) post-transplant. Concordantly, in vitro RAPA inhibited the secretion of CCL2 and CCL3 by monocytes. Rapamycin does not adversely affect intrahepatic islet engraftment in the mouse, and potentially improves islet engraftment in humans by an anti-inflammatory mechanism.

UR - http://www.scopus.com/inward/record.url?scp=79953251890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953251890&partnerID=8YFLogxK

M3 - Article

C2 - 21084848

AN - SCOPUS:79953251890

VL - 1

SP - 42

EP - 49

JO - Islets

JF - Islets

SN - 1938-2014

IS - 1

ER -